Trials / Unknown
UnknownNCT04798612
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Zealand University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this randomized double-blinded placebo-controlled phase 2 study is to determine efficacy of preoperative treatment with interferon-alfa2a in patients with pMMR colon cancer on perioperative immune suppression and infiltration of lymphocytes in the primary tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegasys | 45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between |
| DRUG | Saline | 0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between |
Timeline
- Start date
- 2023-08-14
- Primary completion
- 2025-08-01
- Completion
- 2025-12-01
- First posted
- 2021-03-15
- Last updated
- 2023-08-18
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04798612. Inclusion in this directory is not an endorsement.